A new installment of RGX skins arriving soon can complete your VALORANT collection. Here's everything you need to know. Is this leaked bundle the real deal? New images purport to show VALORANT's ...

The new skin collection has a Blade with an insane animation. The new skin bundle Overdrive are about to hit your VALORANT shop. Chromedek and Sentinels of Light 2.0 are expiring from the banner ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. RegenXBio ( (RGNX)) has issued an ...

The company expects to complete pivotal enrollment for RGX-202 in October 2025 and report topline data in early 2026, with a BLA submission targeted for mid-2026 and a commercial launch potential by ...

Last Wednesday, REGENXBIO Inc (NASDAQ:RGNX) reported additional interim safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy ages 4 to11 ...

Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Recent clinical data shows RGX-121 can address neurological decline, a major ...

The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.’s (NASDAQ:RGNX) Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for ...

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “A one-time in-office procedure with RGX-314 gene ...

Primary endpoint of CSF HS D2S6 reduction at week 16 met; strong correlation to neurodevelopmental outcomes at 1 year, supporting HS D2S6 as surrogate biomarker reasonably likely to predict clinical ...